Scientists in Portugal have created a vaccine based on nanotechnology which can prevent the development of skin cancer in mice.
The nanovaccine, which consists of components of skin cancer cells, was developed by scientists from the Faculty of Pharmacy of the University of Lisbon, an EARA member, in collaboration with Tel Aviv University.
This nanovaccine does not target tumor cells directly, but instead uses the body's immune system to achieve selective destruction of cancer cells.
These results are extremely relevant for cancer patients, preventing the spread of cancer through the body.
“The use of animals in research is essential as it enables us to discover and develop new treatments. Animal models have greatly improved our understanding of human biology and health. They also help ensure the effectiveness and safety of new treatments.”
Cecília Maria Pereira Rodrigues, Coodinator of the Department of Biochemistry and Human Biology at the Faculty of Pharmacy of the University of Lisbon.